menu search

SGMT / Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced that management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24, 2023, at 3:00 p.m. ET / 12:00 p.m. PT. Read More
Posted: Oct 18 2023, 16:05
Author Name: GlobeNewsWire
Views: 092153

SGMT News  

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

By GlobeNewsWire
October 18, 2023

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing no more_horizontal

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

By Seeking Alpha
September 27, 2023

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows pro more_horizontal


Search within

Pages Search Results: